Another reason to use low-dose chemotherapy – a comment

Posted on December 2nd, 2016 by Blog Author

The results of a recent study endorse the approach being taken by Noxopharm in using NOX66 to allow low dosages of chemotherapy to be used…much lower than currently in general use. The obvious advantage we are pursuing with NOX66 is that chemotherapy potentially could be used at levels unlikely to cause any side-effects, making life […]

Read More

November 2016 CEO Blog: Questions from the floor

Posted on November 29th, 2016 by Blog Author

Our AGM last Wednesday in Melbourne and General Briefing last Friday in Sydney brought out some questions from the floor that I thought it worthwhile mentioning for those not able to attend.   Q.Are we looking to raise capital? No. We have sufficient funds to take us through to 2018. If we are successful in […]

Read More

Behind Noxopharm’s Announcement About the Chemotherapy Study

Posted on October 27th, 2016 by Blog Author

The details about the Phase 1 study announced yesterday are available at: https://clinicaltrials.gov/show/NCT02941523 Our main objective in this study is to see if NOX66 can make tumours respond to chemotherapy once they have become fully drug-resistant, and to do so using low dosages of chemotherapy. That’s an ambitious and novel objective, but one that in […]

Read More

October 2-month update by Dr Graham Kelly

Posted on October 7th, 2016 by Blog Author

It’s been 2 months since the listing and IPO. The first few months in the life of a drug development company is all about laying foundations. Everyone is looking for news flow as evidence of activity, but that requires first building the platforms that will deliver the news flow.  As the platforms are progressively built, […]

Read More

Sept 7 2016 NOX66 and Radiotherapy by Dr Graham Kelly

Posted on September 7th, 2016 by Blog Author

In a recent ASX announcement, we made mention of opening up a second clinical front for NOX66, that being to use it in conjunction with radiotherapy.   Our objective is to open up two Phase 1 studies of NOX66 + radiotherapy over the next 6 months. These will complement the NOX66 + chemotherapy study we […]

Read More

5-Sep-2016: NOX66 Technology Explained by Dr Graham Kelly

Posted on September 5th, 2016 by Blog Author

SEPTEMBER 5, 2016:   NOX66 TECHNOLOGY EXPLAINED       by Dr Graham Kelly   Here is an obvious question: Idronoxil was tested in over 400 cancer patients over a 10-year period. In the end, it didn’t work in enough patients to warrant the investment to continue to bring it to market. So why do we think we can […]

Read More

August 12, 2016: First Clinical Study explained by Dr Graham Kelly

Posted on August 12th, 2016 by Blog Author

Welcome to this first blog, which I will use to expand on the details of our upcoming clinical study. It’s a somewhat unusual design, so worth a moment or two to look at in some detail. The first thing to comment on is why we are conducting the study in Eastern Europe and not Australia. […]

Read More